Impact of a Simple Inexpensive Quality Assurance Effort on Physician's Choice of Thrombolytic Agents and Door-to-Needle Time: Implication for Costs of Management.

Abstract:

:The objective of this study were to assess the impact of a quality assurance effort on the door-to-needle time and the choice of thrombolytic agent for the management of acute myocardial infarction in the emergency department. The study design involved a prospective collection of data on a series of consecutive patients who received a thrombolytic agent for a presumed acute myocardial infarction. The study was carried out in the emergency department of a major university urban tertiary care center. A total of 349 patients were studied from September 1989 to March 1994. The quality assurance program began in 1989 and included chart review of all patients receiving thrombolytic therapy, with special attention to all patients with door-to-needle times >60 minutes to identify causes for delay. Feedback was directed to pharmacy, nursing, and physician staff. Biannual reports were distributed throughout the hospital and the emergency department. Nursing-specific feedback led to the development of protocols for all aspects of the delivery of thrombolytic agents. The choice of thrombolytic agent was not dictated by the protocol, but the physician staff was continuously updated on the results of the latest clinical trials comparing one thrombolytic agent with another. The mean age was 58 years for men and 67 years for women in this cohort consisting of 78% men and 22% women. Thirty-seven percent of the myocardial infarctions were in an anterior location and 56% were in an inferior location. The median duration of chest pain before presentation to the emergency department was 120 minutes. Hospital mortality was 3%. Median door-to-needle time fell from 46 (1989-1991) to 36 (1992-1994) minutes, P& < 0.01. The percentage of patients with a door-to-needle time >60 minutes decreased from 35% (1989-1991) to 16% (1992-1994) minutes, P < 0.0001. Corresponding with the ISIS-3 report, there was a significant increase in the proportion of patients receiving streptokinase over the first 3 years of the study (P < 0.0001), which changed to a trend toward increased utilization of tissue plasminogen activator with the GUSTO report in the final 6 months of the study. In conclusion, a quality assurance program led to a significant reduction in the door-to-needle time, and recent megatrials were found to influence the choice of thrombolytic agent used.

journal_name

J Thromb Thrombolysis

authors

Guidry UA,Paul SD,Vega J,Harris C,Chaturvedi R,O'Gara PT,Eagle KA

doi

10.1023/A:1008834230015

subject

Has Abstract

pub_date

1998-05-01 00:00:00

pages

151-157

issue

2

eissn

0929-5305

issn

1573-742X

journal_volume

5

pub_type

杂志文章
  • Sodium-hydrogen exchange and platelet function.

    abstract::On stimulation of platelets with agonists, for example, thrombin, a rapid rise in intracellular pH is observed. This alkalinization is mediated by an increase in transport activity of the Na(+)/H(+) exchanger isoform NHE1. In addition to this Na(+)/H(+) exchange mechanism, platelets express bicarbonate/chloride exchan...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1008986329267

    authors: Rosskopf D

    更新日期:1999-07-01 00:00:00

  • Lack of alpha 2-antiplasmin enhances ADP induced platelet micro-aggregation through the presence of excess active plasmin in mice.

    abstract:BACKGROUND:The role of alpha2-antiplasmin (alpha2-AP) on platelet aggregation was investigated using mice deficient in alpha2-AP (alpha2-AP(-/-)) or using wild type mice (alpha2-AP(+/+)). METHODS:Blood samples were taken from each mouse under anesthesia with ether and platelet rich plasma (PRP) was prepared. Platelet ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1025096609558

    authors: Takei M,Matsuno H,Okada K,Ueshima S,Matsuo O,Kozawa O

    更新日期:2002-12-01 00:00:00

  • Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?

    abstract::Patients with Coronavirus-associated disease-2019 (COVID-19) display alterations of the hemostatic system and the presence of a prothrombotic status frequently leading to vascular complications. However, the impact of COVID-19 on platelet activity, aggregation and agglutination still needs to be clarified. We measured...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02339-6

    authors: Ruberto F,Chistolini A,Curreli M,Frati G,Marullo AGM,Biondi-Zoccai G,Mancone M,Sciarretta S,Miraldi F,Alessandri F,Ceccarelli G,Barone F,Santoro C,Alvaro D,Pugliese F,Pulcinelli FM,Policlinico Umberto I COVID-19 Group.

    更新日期:2021-01-02 00:00:00

  • Reasons for exclusion from intravenous thrombolysis in stroke patients admitted to the Stroke Unit.

    abstract::Intravenous (IV) thrombolysis is the treatment in ischemic stroke, but only the minority of patients receive this medication. The primary objective of this study was to explore the reasons associated with the decision not to offer IV thrombolysis to stroke patients admitted to the Stroke Unit (SU). We conducted a retr...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1406-8

    authors: Cappellari M,Bosco M,Forlivesi S,Tomelleri G,Micheletti N,Carletti M,Bovi P

    更新日期:2016-11-01 00:00:00

  • Interhospital transfer on intravenous thrombolysis in patients with acute ischemic stroke in three chinese municipal stroke centers.

    abstract::We included acute ischemic stroke (AIS) patients who received recombinant tissue plasminogen activator (rt-PA) at three stroke centers via either interhospital transfer or direct presentation and compared the clinical outcomes and time metrics to analyze the impact of interhospital transfer on intravenous thrombolysis...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s11239-019-01912-y

    authors: Ding Y,Ji Z,Ma L,Zhai T,Gu Z,Niu J,Liu Y

    更新日期:2019-11-01 00:00:00

  • Excessive fibrinolysis detected with thromboelastography in a case of amniotic fluid embolism: fibrinolysis may precede coagulopathy.

    abstract::Amniotic fluid embolism (AFE) is a catastrophic condition in the peripartum period and still remains as a leading cause of maternal death. Although over 80% of cases of AFE cases are accompanied by coagulopathy, the pathology of disseminated intravascular coagulation is not well understood not only because of its rari...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02237-x

    authors: Fudaba M,Tachibana D,Misugi T,Nakano A,Koyama M

    更新日期:2020-07-29 00:00:00

  • Duration of anticoagulation for venous thromboembolism.

    abstract::The duration of oral anticoagulant therapy for venous thromboembolism (VTE) depends on the risk of recurrence if treatment is stopped and the risk of bleeding if treatment is continued. If the risk of recurrence is low (e.g., thrombosis provoked by a major reversible risk factor such as surgery), 3 months of treatment...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1012790511790

    authors: Kearon C

    更新日期:2001-09-01 00:00:00

  • Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity.

    abstract::Hyperhomocysteinemia (HHcy) affects haemostasis and shifts its balance in favour of thrombosis. In vitro and in vivo studies suggested that HHcy may impair fibrinolysis either by influencing the plasma levels of fibrinolytic factors or by altering the fibrinogen structure. We investigated the influence of mild HHcy le...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-013-0981-1

    authors: Cellai AP,Lami D,Antonucci E,Liotta AA,Rogolino A,Fedi S,Fiorillo C,Becatti M,Cenci C,Marcucci R,Abbate R,Prisco D

    更新日期:2014-07-01 00:00:00

  • A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.

    abstract::The objective was to compare the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ticagrelor with clopidogrel among subjects of Hispanic ethnicity, as the PD and PK effects of antiplatelet agents among Hispanics are not specifically known. This was a randomised, open-label, crossover PD/PK study of 40 Hispanic...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-014-1135-9

    authors: Price MJ,Clavijo L,Angiolillo DJ,Carlson G,Caplan R,Teng R,Maya J

    更新日期:2015-01-01 00:00:00

  • Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents.

    abstract:BACKGROUND:Early change in local intracoronary hemostasis following drug-eluting (DES) and bare metal stent (BMS) implantation has never been assessed in stable angina patients. METHODS:Markers of local platelet activation (soluble glycoprotein V [sGPV] and P-Selectin [CD62P]), coagulation activation (tissue factor [T...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-008-0266-2

    authors: Mahemuti A,Meneveau N,Seronde MF,Schiele F,Descotes-Genon V,Ecarnot F,Blonde MC,Mercier M,Racadot E,Bassand JP

    更新日期:2009-10-01 00:00:00

  • Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature.

    abstract::Plasminogen activator inhibitor (PAI-1), a member of the serine protein family, is the most active in vivo inhibitor of fibrinolysis induced by plasminogen, tissue plasminogen activator (tPA), and urokinase type plasminogen activator (uPA). While the association between elevated PAI-1 and thrombogenesis has been well ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1008907001042

    authors: Senno SL,Pechet L

    更新日期:1999-08-01 00:00:00

  • Synchronous cardiocerebral infarction in the era of endovascular therapy: which to treat first?

    abstract::A cardiocerebral ischemic attack (CCI) or a concurrent acute ischemic stroke (AIS) and myocardial infarction (AMI) is a severe event with no clear recommendations for ideal management because of the rarity of the scenario. The narrow time window for treatment and complexity of the treatment decision puts immense press...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-017-1484-2

    authors: Yeo LLL,Andersson T,Yee KW,Tan BYQ,Paliwal P,Gopinathan A,Nadarajah M,Ting E,Teoh HL,Cherian R,Lundström E,Tay ELW,Sharma VK

    更新日期:2017-07-01 00:00:00

  • Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.

    abstract:BACKGROUND:Oxidative stress play an important role triggering platelet/endothelial activation. AGI-1067 is a novel, phenolic antioxidant, and vascular protectant which dose-dependently inhibits PEA biomarkers in vitro. Whether treatment with AGI-1067 alters platelets in vivo is not known. We serially assessed release o...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-008-0233-y

    authors: Serebruany V,Malinin A,Qiu FH,Xu XC,Kunsch C,Scott R,ALPS Study Group.

    更新日期:2009-05-01 00:00:00

  • Direct penetrating and indirect neck trauma as a cause of internal carotid artery thrombosis and secondary ischemic stroke.

    abstract::The following manuscript presents two cases of ischemic stroke secondary to traumatic internal carotid artery thrombosis with concomitant middle cerebral artery thrombosis occurring very rarely in the medico-legal practice. Penetrating neck trauma due to an occupational accident and multiple head and neck trauma secon...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1077-2

    authors: Karnecki K,Jankowski Z,Kaliszan M

    更新日期:2014-10-01 00:00:00

  • Association of TIMI myocardial perfusion grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following ST-segment elevation myocardial infarction.

    abstract:BACKGROUND:Impairment of coronary microvascular perfusion is common among patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). Cardiovascular magnetic resonance imaging (CMR) can identify microvascular obstruction (MO) following reperfusion of S...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-008-0197-y

    authors: Appelbaum E,Kirtane AJ,Clark A,Pride YB,Gelfand EV,Harrigan CJ,Kissinger KV,Manning WJ,Gibson CM

    更新日期:2009-02-01 00:00:00

  • Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.

    abstract::Arterial thrombosis is the leading causes of morbidity and mortality worldwide, whereas venous thrombosis is the most common preventable cause of hospital death. In either case, venous and arterial thrombosis should be considered autonomous entities, with only minor overlaps in terms of risk factors, predisposing cond...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-012-0748-0

    authors: Lippi G,Favaloro EJ,Franchini M

    更新日期:2012-10-01 00:00:00

  • Increased soluble GPVI levels in cirrhosis: evidence for early in vivo platelet activation.

    abstract::Cirrhosis is a consequence of prolonged liver injury and is characterised by extensive tissue fibrosis: the deposition of collagen-rich extracellular matrix. The haemostatic balance is disordered in cirrhosis and coagulation activation appears to promote fibrosis. In spite of recent studies demonstrating a role for an...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1401-0

    authors: Egan K,Dillon A,Dunne E,Kevane B,Galvin Z,Maguire P,Kenny D,Stewart S,Ainle FN

    更新日期:2017-01-01 00:00:00

  • Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment.

    abstract::Tumour necrosis factor alpha (TNF-alpha) and interlekin-6 (IL-6) are key inflammatory cytokines in the pathogenesis of rheumatoid arthritis (RA), a disease also associated with endothelial perturbation and increased serum levels of adhesion molecules. As relationships between these processes and molecules are unclear,...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-009-0370-y

    authors: Foster W,Carruthers D,Lip GY,Blann AD

    更新日期:2010-05-01 00:00:00

  • Characteristic and prognosis of acute large vessel occlusion in anterior and posterior circulation after endovascular treatment: the ANGEL registry real world experience.

    abstract::There were limited studies comparing the anterior (AC) and posterior (PC) circulation acute ischemic strokes (AIS). Our study aimed to evaluate distinct features of AC and PC strokes regarding clinical, vascular risk, pathogenesis and outcome factors after endovascular procedures. This multicenter prospective study re...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02054-2

    authors: Huo X,Raynald,Gao F,Ma N,Mo D,Sun X,Song L,Jia B,Pan Y,Wang Y,Liu L,Zhao X,Wang Y,Miao Z,ANGEL investigators.

    更新日期:2020-05-01 00:00:00

  • Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: comment.

    abstract::Kuperman et al. found that patients with anemia had a higher risk of major bleeding (RR 2.84; 95% CI 2.52-3.39) in RIETE database. Anemia appeared to be an independent predictive factor for major bleeding [hazard ratio (HR) 1.95; 95% CI 1.72-2.20] in this registry. Unfortunately, selection bias due to enrolled patient...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 信件,多中心研究

    doi:10.1007/s11239-018-1668-4

    authors: Gaboreau Y,Zenatti N,Vermorel C,Imbert P,Bosson JL,Pernod G

    更新日期:2018-07-01 00:00:00

  • Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

    abstract::Among atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI), rivaroxaban with background antiplatelet therapy significantly reduced the first occurrence of bleeding compared to triple therapy with warfarin. This study hypothesized that total bleeding events, including those beyond the f...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-018-1703-5

    authors: Chi G,Yee MK,Kalayci A,Kerneis M,AlKhalfan F,Mehran R,Bode C,Halperin JL,Verheugt FWA,Wildgoose P,van Eickels M,Lip GYH,Cohen M,Peterson ED,Fox KAA,Gibson CM

    更新日期:2018-10-01 00:00:00

  • Point-of-care testing of coagulation in patients treated with edoxaban.

    abstract::Edoxaban, alongside other direct oral anticoagulants (DOAC), is increasingly used for prevention of thromboembolism, including stroke. Despite DOAC therapy, however, annual stroke rate in patients with atrial fibrillation remains 1-2%. Rapid exclusion of relevant anticoagulation is necessary to guide thrombolysis or r...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02143-2

    authors: Härtig F,Birschmann I,Peter A,Hörber S,Ebner M,Sonnleitner M,Spencer C,Bombach P,Stefanou MI,Kuhn J,Mengel A,Ziemann U,Poli S

    更新日期:2020-10-01 00:00:00

  • Initiation of warfarin therapy: recommendations and clinical pearls.

    abstract::Warfarin is a commonly used medication with a narrow therapeutic index. The initiation of warfarin requires consideration of a variety of factors, which include reviewing the indications and contraindications for this agent, performing a thorough clinical assessment along with a risk-benefit analysis for anticoagulati...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1008833520158

    authors: Erban S

    更新日期:1999-04-01 00:00:00

  • Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.

    abstract::Warfarin is among the ten drugs most commonly involved in adverse drug reactions, has a narrow therapeutic index and complex dosage regimen, exhibits enormous variability dose-response and high risk drug-drug interactions. To analyze the profile of pharmacoepidemiological drug prescriptions for warfarin in patients ad...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-013-1030-9

    authors: Guidoni CM,Obreli-Neto PR,Pereira LR

    更新日期:2014-05-01 00:00:00

  • Outpatient Therapy of Deep Vein Thrombosis.

    abstract::The initial treatment of acute venous thrombosis using low-molecular-weight heparin (LMWH) in the outpatient setting has been shown to be feasible, effective, and safe for selected patients when compared with in-hospital treatment using continuous intravenous heparin. There will always be a significant population of p...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1013232803747

    authors: Pineo GF,Hull RD

    更新日期:1998-01-01 00:00:00

  • The ADP receptor P2Y(1) mediates t-PA release in pigs during cardiac ischemia.

    abstract:BACKGROUND:The endothelial ADP receptor P2Y(1) is responsible for a large part of the reactive hyperemia following cardiac ischemia. Tissue plasminogen activator (t-PA) increases during reactive hyperemia. We postulated that the release of t-PA during reactive hyperemia could be mitigated through blocking the coronary ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0010-3

    authors: Olivecrona GK,Götberg M,Harnek J,Jacobson KA,Jern S,Erlinge D

    更新日期:2007-10-01 00:00:00

  • Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis.

    abstract::A 64-year-old man first developed ligneous conjunctivitis at the age of 58 years after right pulmonary resection because of suspected cancer; otherwise, he had been healthy. Since then, he began to suffer from various forms of chronic pseudomembranous mucositis. Laboratory tests demonstrated that he had 7.8 % of plasm...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1375-y

    authors: Osaki T,Souri M,Song YS,Izumi N,Law R,Ichinose A

    更新日期:2016-08-01 00:00:00

  • Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.

    abstract::Cancer is associated with an increased risk of venous thromboembolism of four to sixfold. Cancer-related interventions such as chemotherapy, hormonal therapy and indwelling central venous catheters also increase the risk of venous thromboembolism. Low molecular weight heparin for at least 3-6 months is the current sta...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-018-1783-2

    authors: Franco-Moreno A,Cabezón-Gutiérrez L,Palka-Kotlowsa M,Villamayor-Delgado M,García-Navarro M

    更新日期:2019-04-01 00:00:00

  • Anticoagulation for the treatment of venous thromboembolism in patients with brain metastases: a meta-analysis and systematic review.

    abstract::The risk benefit decision in providing anticoagulation for patients with brain metastases is amongst the most difficult decisions faced by clinicians. The purpose of our study was to evaluate both the risk of intracerebral hemorrhage (ICH) associated with anticoagulation therapy and the effect of anticoagulation on su...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s11239-017-1536-7

    authors: Hunter BD,Minichiello T,Bent S

    更新日期:2017-10-01 00:00:00

  • Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infar

    abstract::The benefits of thrombolytic therapy in the treatment of acute myocardial infarction are incontrovertible. Large-scale studies combining angiographic and clinical end-points have demonstrated a perfusion-mortality relationship, with the highest survival rate among patients with early restoration of TIMI grade 3 corona...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/BF01062706

    authors: Moliterno DJ,Harrington RA,Califf RM,Rapold HJ,Topol EJ

    更新日期:1995-01-01 00:00:00